Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Gen ADC Platform November 5, 2024
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture October 29, 2024
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a MSA for n.c.a. Lutetium-177 October 22, 2024
AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors October 22, 2024
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche October 22, 2024
Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology October 22, 2024
Nona Biosciences announced a strategic collaboration with OverT Bio to develop next-generation cell therapies for solid tumors October 15, 2024
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into 1L HCC Pivotal Trial October 15, 2024
Exelixis and Merck to Evaluate Zanzalintinib in Combination With KEYTRUDA in Head and Neck Cancer and in Combination With WELIREG in RCC October 15, 2024
Ono Enters into License Agreement for LCB97 to generate novel ADC candidates by leveraging ConjuAll™ ADC platform with LigaChem Biosciences October 15, 2024
MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy October 15, 2024
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors October 15, 2024
Boehringer Ingelheim and Circle Pharma announce new research collaboration to develop a novel precision cancer treatment October 15, 2024
Cellipont Bioservices and Mongoose Bio to Advance TCR-T therapy MGB-001 for Multiple Cancers October 9, 2024
Aktis Oncology announces $175 million oversubscribed series B financing to further advance its proprietary radiopharmaceutical pipeline October 8, 2024
ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA in Patients with Solid Tumors October 8, 2024
